SCHEDULE: Vanguard Group Reports 0% Stake in Rhythm Pharma

The Vanguard Group has amended its Schedule 13G filing for Rhythm Pharmaceuticals Inc., reporting a 0% beneficial ownership stake following an internal corporate realignment.

Summary

• The Vanguard Group filed an Amendment No. 3 to its Schedule 13G for Rhythm Pharmaceuticals Inc. regarding its Common Stock.
• The filing indicates that The Vanguard Group now beneficially owns 0% of Rhythm Pharmaceuticals Inc.'s Common Stock, representing 0% of the class.
• This change is attributed to an internal realignment within The Vanguard Group, Inc. that occurred on January 12, 2026.
• Following the realignment, certain subsidiaries or business divisions of The Vanguard Group, Inc. will report beneficial ownership separately, and The Vanguard Group, Inc. itself no longer has, or is deemed to have, direct beneficial ownership over these securities.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a slightly negative development for Rhythm Pharmaceuticals due to the optics of a major institutional investor reporting 0% ownership, despite the administrative explanation from Vanguard. The market may react to the headline rather than the underlying reason.

Negatives

• The reporting of 0% beneficial ownership by The Vanguard Group, a major institutional investor, could be perceived negatively by the market for Rhythm Pharmaceuticals Inc., despite the administrative explanation.

Risks

• The primary risk for Rhythm Pharmaceuticals Inc. is the potential for negative market perception and investor sentiment due to a major institutional investor reporting a 0% stake, even if it's an internal administrative change for Vanguard.

Future Outlook

No forward-looking statements or guidance regarding Rhythm Pharmaceuticals Inc.'s performance or operations are provided in this ownership disclosure.

Industry Context

StockSavvy.ai notes that internal realignments by large asset managers like The Vanguard Group are administrative in nature and typically reflect changes in internal reporting structures rather than a direct change in investment thesis regarding the underlying company. However, the immediate optics of a 0% reported stake from the parent entity can sometimes be misinterpreted by the market.

Stakeholder Impact

• Shareholders: Existing shareholders might react negatively to the perceived divestment by a major institutional investor, potentially leading to short-term price volatility.
• Potential Investors: New investors might view the 0% reported stake by The Vanguard Group as a signal of reduced institutional interest, even if the underlying assets are still held by Vanguard's subsidiaries.

Next Steps

• The Vanguard Group's subsidiaries or business divisions are expected to report their beneficial ownership separately in future filings, in accordance with SEC Release No. 34-39538.

Key Dates

Recommendation

While the filing indicates a 0% direct beneficial ownership by The Vanguard Group due to an internal realignment, it does not necessarily imply a complete divestment by all Vanguard-managed funds. The market might react negatively to the headline, but a deeper understanding reveals it's an administrative change. Investors should hold and monitor subsequent filings from Vanguard's subsidiaries to understand the true aggregate institutional ownership.

Keywords

Rhythm Pharmaceuticals, Vanguard Group, Schedule 13G, Beneficial Ownership, Institutional Ownership, Common Stock, SEC Filing, Investment Realignment